Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Dallas, Texas 75247


Purpose:

A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered by the Intraject system.


Study summary:

A single center, randomized, single-dose, open-label, partial-block, four-period, four-way crossover study in 54 healthy adult subjects to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered by the Intraject system compared to IMITREX STATdose at three injection sites (abdomen, thigh, and arm.)


Criteria:

Inclusion Criteria: - Healthy subjects - Negative serum pregnancy test - Female subjects of child-bearing potential must agree to use acceptable birth control 3 weeks prior to and 2 weeks after study dosing. - Body Mass Index (BMI) and sufficient subcutaneous thickness, in the opinion of the investigator, for an injection into the abdomen, arm and thigh - Non-tobacco user - Adequate venous access in the left or right arm to allow collection of a number of blood samples - Fluent in the English language - Provide written informed consent to participate in the study and be willing to comply with the study procedures Exclusion Criteria: - History within the previous 2 years of drug or alcohol dependence - Evidence of clinically relevant oral, cardiovascular, hematologic, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder - History of epilepsy or other neurologic disease - History of coronary disease, peripheral vascular disease, cerebrovascular accident, transient ischemic attack, uncontrolled hypertension, or signs/symptoms of ischemic heart disease - History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or similar drugs including sulphonamides - History of scleroderma or any skin condition that may adversely affect the injection or absorption of subcutaneously administered medications - Tattoos or birthmarks in the lateral thigh, abdominal area or arm (deltoid) that are large enough to restrict injection site selection and/or evaluation - Positive screening test for HIV antibodies, Hepatitis B surface antigen, or Hepatitis C antibody - Positive results on illicit drug test at Screening or at Check-in - Use of any prescription medication


NCT ID:

NCT00614029


Primary Contact:

Principal Investigator
Patricia Chandler, MD
Covance


Backup Contact:

N/A


Location Contact:

Dallas, Texas 75247
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.